Novel Drug Delivery Systems in the management of CNS Disorders: Chapter 13 - Role of novel drug delivery systems in managing Alzheimer's disease

Alzheimer's disease (AD) represents the most prevalent kind of cognition, responsible for further approximately 46 million reported cases globally. The ongoing rise of Alzheimer's disease necessitates the rapid growth of really efficacious preventative and restorative therapy techniques. ACh (Acetylcholinesterase) blockers and NMDA (N-methyl-d-aspartate) receptor inhibitors are the two types of medications that are authorized for the management of Alzheimer's disease. The limited accessibility to the nervous system because of the BBB (blood-brain barrier), poor bio-distribution, and lowered ADME features of certain medications limit their clinical efficiency. Furthermore, the medications are said to have unfavorable adverse reactions. To overcome these challenges, various route of administration or DDSs (drug delivery systems) have really been extensively used. A mechanistic paradigm completely explains the development of Alzheimer's disease. This chapter also covered FDA-approved medications as well as clinical trial pharmaceuticals.